Once dismissed as less effective, the vaccine now seems to be preventing infections and illness about as well as the two mRNA options. By Apoorva Mandavilli Roughly 17 million Americans received the ...

As if the talc product liability lawsuits weren’t enough headache for Johnson & Johnson, the New Jersey pharma is now facing another lawsuit from patients, this time about a recent data breach. J&J ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

The protection of personal data has become a critical concern in today's digital age, especially when sensitive information ...

Although federal EHR technology investments had disappointing results, they were necessary to start digitizing the nation's health care data and set the stage for a promising future. An architecture ...

Economists on the left and right criticized E.J. Antoni for misunderstanding the data he would now oversee. By Ben Casselman Alan Rappeport and Lydia DePillis On Aug. 1, shortly after the Bureau of ...